Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
April 04 2006 - 7:30AM
PR Newswire (US)
SAN DIEGO, April 4 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced the exercise by
its underwriters of an over-allotment option to purchase 1,500,000
shares of common stock associated with its follow-on stock offering
that priced on March 29, 2006. Including the over-allotment shares,
the offering will total 11,500,000 shares at $46.50 per share,
resulting in expected net proceeds to the company of approximately
$508 million. Morgan Stanley & Co. Incorporated is acting as
the sole bookrunning and co-lead manager for the offering. Goldman,
Sachs & Co. is acting as a co-lead manager of the offering.
Co-managers for the offering are Bear, Stearns & Co. Inc. and
Lehman Brothers Inc. Amylin Pharmaceuticals is a biopharmaceutical
company committed to improving lives through the discovery,
development and commercialization of innovative medicines. Copies
of the prospectus supplement may be obtained from the Prospectus
Department of Morgan Stanley & Co. Incorporated (1585 Broadway,
New York, New York 10036, phone 212-761-6775, fax 212-761-0211).
DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta,
Senior Vice President, Finance and Chief Financial Officer of
Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024